摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-deoxy-d-glucopyranose | 61-58-5

中文名称
——
中文别名
——
英文名称
2-deoxy-d-glucopyranose
英文别名
2-deoxy-[3H]-D-glucose;[3H]-2-deoxy glucose;2-deoxy-D-glucose;2-DG;[3H]-2-deoxy-D-glucose;2-deoxy-hexopyranose;2-Deoxyhexopyranose;6-(hydroxymethyl)oxane-2,4,5-triol
2-deoxy-d-glucopyranose化学式
CAS
61-58-5;13299-15-5;13299-16-6;14215-77-1;14215-78-2;20789-85-9;23568-30-1;25494-04-6;34339-39-4;34339-40-7;34339-46-3;34339-47-4;114717-20-3;114717-21-4;137491-75-9;137491-76-0
化学式
C6H12O5
mdl
MFCD02179704
分子量
164.158
InChiKey
PMMURAAUARKVCB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    175 °C
  • 沸点:
    411.0±45.0 °C(Predicted)
  • 密度:
    1.533±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.6
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    90.2
  • 氢给体数:
    4
  • 氢受体数:
    5

SDS

SDS:4b091a4d5b5da81ae27a8f19dafb6a20
查看

文献信息

  • [EN] CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS<br/>[FR] CONJUGUÉS POUR TRAITER LES MALADIES PROVOQUÉES PAR DES CELLULES EXPRIMANT PSMA
    申请人:ENDOCYTE INC
    公开号:WO2014078484A1
    公开(公告)日:2014-05-22
    The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    本发明涉及对病原细胞群体进行诊断、成像和/或治疗。具体来说,本发明涉及利用能够靶向PSMA表达细胞的化合物对由PSMA表达细胞引起的疾病,如前列腺癌细胞,进行诊断、成像和/或治疗。
  • [EN] HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES<br/>[FR] COMPOSES ANTIVIRAUX HETEROCYCLIQUES COMPORTANT DES GROUPES FONCTIONNELS METABOLISABLES ET LEURS UTILISATIONS
    申请人:RIGEL PHARMACEUTICALS INC
    公开号:WO2005097760A1
    公开(公告)日:2005-10-20
    The present invention relates to substituted prodrug and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.
    本发明涉及替代前药及其组合物,用于治疗或预防丙型肝炎病毒(HCV)感染。具体而言,本发明涉及替代二苯基、二杂环芳基和混合苯基杂环芳基替代的五元杂环化合物的前药,包含这些化合物的组合物以及利用这些化合物和组合物来抑制HCV复制和/或增殖作为治疗方法,以治疗和/或预防人类和动物中的HCV感染。
  • [EN] METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES<br/>[FR] PROCÉDÉS DE TRAITEMENT DU CANCER PAR CIBLAGE DE MACROPHAGES ASSOCIÉS À UNE TUMEUR
    申请人:ENDOCYTE INC
    公开号:WO2016085967A1
    公开(公告)日:2016-06-02
    Methods for treating cancers using one or more compounds comprising a folate receptor binding ligand attached to a drug via a linker are described. Methods for treating cancers using one or more compounds comprising a folate receptor binding ligand attached to a drug via a linker to target tumor associated macrophages are described.
    描述了使用一个或多个包含叶酸受体结合配体通过连接剂连接到药物的化合物来治疗癌症的方法。描述了使用一个或多个包含叶酸受体结合配体通过连接剂连接到药物来靶向肿瘤相关巨噬细胞以治疗癌症的方法。
  • [EN] TUCARESOL DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE TUCARESOL ET LEURS UTILISATIONS
    申请人:BEYONDSPRING PHARMACEUTICALS INC
    公开号:WO2021096811A1
    公开(公告)日:2021-05-20
    Disclosed herein are tucaresol derivative compound and composition containing the same. Also disclosed herein are methods of enhancing immune response in a subject by administering the tucaresol derivative compound or by co-administering the tucaresol derivative compound and one or more additional agents. Also disclosed herein are use of the tucaresol derivative compound and composition containing the same in the manufacture of a medicament for treating cancer or enhancing immune response in a subject.
    本文披露了一种tucaresol衍生物化合物和含有该化合物的组合物。本文还披露了通过给予tucaresol衍生物化合物或同时给予tucaresol衍生物化合物和一个或多个额外药剂来增强受试者的免疫反应的方法。本文还披露了将tucaresol衍生物化合物和含有该化合物的组合物用于制造用于治疗癌症或增强受试者免疫反应的药物的用途。
  • Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
    申请人:Singh Rajinder
    公开号:US20050239751A1
    公开(公告)日:2005-10-27
    The present invention relates to substituted prodrug and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.
    本发明涉及代替前药及其组合物,用于治疗或预防丙型肝炎病毒(HCV)感染。具体而言,本发明涉及取代二苯基、双杂环芳基和混合苯基杂芳基取代的五元杂环化合物的前药,包括该化合物的组合物,以及使用这些化合物和组合物来抑制HCV复制和/或增殖,作为治疗和/或预防人类和动物HCV感染的治疗方法。
查看更多